Cadence Neuroscience raises $26M to support epilepsy neuromod therapy

Neurmodulation technology developer Cadence Neuroscience announced that it secured $26 million in a Series B financing round.

The Angelini Lumira Biosciences Fund led the round. It also included new investors F-Prime Capital, LivaNova USA, Angelini Ventures, Spectrum Financial Services and Mayo Clinic. Series A lead investor, Jazz Venture Partners, also contributed.

In connection with the financing, Gerry Brunk of Lumira and Kevin Chu of F-Prime joined Cadence Neuroscience’s board.

Cadence develops a novel neuromodulation therapy for treating pediatric and adult patients with focal drug-resistant epilepsy. The therapy utilizes chronic subthreshold cortical stimulation. It modulates EEG biomarkers associated with epilepsy to reduce or eliminate seizures. Chu called the “precise, patient specific” stimulation method Cadence develops “unique and exciting.”

“We believe Cadence’s platform solution has the poten…

Read more
  • 0